Logo

CSL Behring Presents Results of Etranacogene Dezaparvovec in P-III (HOPE-B) Trial for the Treatment of Hemophilia B at EAHAD 2022

Share this

CSL Behring Presents Results of Etranacogene Dezaparvovec in P-III (HOPE-B) Trial for the Treatment of Hemophilia B at EAHAD 2022

Shots:

  • The P-III (HOPE-B) trial evaluates the safety & efficacy of etranacogene dezaparvovec in 54 male patients with hemophilia B
  • The results showed that patients experienced a stable & durable increase in mean FIX activity & hemostatic protection @18mos. at the single infusion of etranacogene dezaparvovec, 64% reduction in ABR for all bleeds & 77% in FIX-treated bleeds, 98% discontinued use of prophylaxis, 97% reduction in mean unadjusted annualized FIX consumption & was well-tolerated
  • Etranacogene Dezaparvovec is an AAV5-based gene therapy. Additionally, preclinical/clinical data showed that the therapy may be clinically effective in ~95% of patients with pre-existing Abs to AAV vectors

Ref: PR Newswire | Image: CSL Behring

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions